Prenetics, a Hong Kong-based DNA biotechnology company specializing in pharmacogenomics, raised US$10M in Series A funding.
The round was led by Ping An Ventures, the venture capital arm of Ping An Insurance Group, with participation from Venturra Capital, Capital Union Investments and existing investors 500 Startups, and Coent Venture Partners.
Led by Danny Yeung, CEO, Prenetics is a precision medicine life sciences company focused on personalized, predictive and preventive treatments. Its proprietary iGenes test allows physicians to help patients identify the right drug, right dosage and to list out potential adverse drug effects (ADEs), based on one’s genetic profile.
Originated as part of the Biomedical Science Research Centre in City University Hong Kong, Prenetics officially spun off as an independent company in 2009.
FinSMEs
16/03/2016